2. Disease Areas
  3. Infection
  4. Coronavirus Infection
  5. hCoV-OC43

hCoV-OC43

hCoV-OC43 is a seasonal coronavirus that mainly replicates in the epithelial cells of the upper respiratory tract, usually causing mild to moderate common cold-like symptoms, though it can occasionally result in severe complications such as pneumonia and central nervous system infections.

hCoV-OC43 (5):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180673
    Mpro/RdRp-IN-1
    Mpro/RdRp-IN-1 (Compound 1) is a dual-target inhibitor against SARS-CoV-2, targeting RdRp (EC50 = 25.45) and Mpro (IC50 = 125.4 μM). Mpro/RdRp-IN-1 exhibits EC₅₀ for HCoV-OC43 of 4.79 μM, and the selectivity index (SI) is 10.89. Mpro/RdRp-IN-1 can be used for studying SARS-CoV-2 and HCoV-OC43 infections.
    Mpro/RdRp-IN-1
  • HY-178696
    UAWJ9-36-3 2663864-31-9
    UAWJ9-36-3 is a Mpro and cathepsin L (IC50: 1.81 μM) inhibitor. UAWJ9-36-3 shows potent binding and enzymatic inhibition against the Mpros from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 demonstrates broad-spectrum antiviral activity against not only SARS-CoV-2, but also the common human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E.
    UAWJ9-36-3
  • HY-161789
    PROTAC SARS-CoV-2 Mpro degrader-3
    PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
    PROTAC SARS-CoV-2 Mpro degrader-3
  • HY-183761
    Antiviral agent 86
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections.
    Antiviral agent 86
  • HY-181997
    LDLRAP1-IN-1 3093624-24-6
    LDLRAP1-IN-1 (Compound B19) is a LDLRAP1 inhibitor and antiviral agent, with an IC50 of 4.98 μM for disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 covalently modifies the C119 residue of LDLRAP1 at the LDLRAP1-LDLR binding interface, thereby disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 exhibits antiviral activity against HCoV-OC43.
    LDLRAP1-IN-1